Non-small cell lung cancer

News

Bayer's Hyrnuo moves first-line for lung cancer in China

Bayer's oral HER2 inhibitor Hyrnuo has been approved in China as a frontline therapy for advanced, HER2-mutant non-small cell lung cancer.

News

Hutchmed, AZ file Orpathys for lung cancer on ESMO data

Hutchmed/AstraZeneca's Orpathys is now under review in Europe and Japan for MET-driven/EGFR-mutated lung cancer, shortly after it was filed in the US.

News

ESMO26: Roche's KRAS drug tops approved drugs in NSCLC

In the Krascedo-1 trial, Roche's KRAS G12C inhibitor divarasib met high expectations, with a head-to-head win over Lumakras and Krazati.

News

ESMO26: Sac-TMT delivers the goods in PD-L1-negative NSCLC

Kelun and MSD's TROP2-directed ADC, sac-TMT, reduced the risk of disease progression or death by 51% when used first-line in PD-L1-negative NSCLC.

News

ESMO26: Tango sees 82% ORR with combo in pancreatic cancer

A study of RevMed's Rasonque with Tango's vopimetostat has raised hopes of a new combination therapy for aggressive pancreatic cancer.

News

Iambic prices its IPO, seeking to raise up to $160m

AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.

Bayer's Hyrnuo moves first-line for lung cancer in China

Hutchmed, AZ file Orpathys for lung cancer on ESMO data

ESMO26: Roche's KRAS drug tops approved drugs in NSCLC

ESMO26: Sac-TMT delivers the goods in PD-L1-negative NSCLC

ESMO26: Tango sees 82% ORR with combo in pancreatic cancer

Iambic prices its IPO, seeking to raise up to $160m

UK backs startup Potential Sciences' AI-powered drug hunt

Discover a new era of healthcare panel engagement: Grounded ...

Non-small cell lung cancer

Editor's Picks